

Amendment B
U.S. Appl. 09/942,174
May 11, 2004


Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

Claims 1-7 (canceled).

8. (currently amended) A compound of the Formula I



wherein

Z₁ is selected from the group consisting of CH₂, O, CH₂O, NH, S, SO, CH(OH) and SO₂;

Z₂ is a 1-5 carbon linker optionally containing one or more heteroatom selected from the group consisting of O, S and N; or

Z₁-Z₂ optionally contain a carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, or acyl group; wherein the carbon and nitrogen atoms of Z₁-Z₂ are optionally substituted by a substituent selected from the group consisting of alkyl, alkoxy, thioalkyl, alkylsulfone, aryl, alkoxyalkyl, alkylamino, heteroaryl, hydroxyl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl, haloalkyl and acylamino;


n is an integer selected from the group consisting of zero [[0]], 1 ~~or~~ and 2;

Amendment B
U.S. Appl. 09/942,174
May 11, 2004

R^c is selected from the group consisting of hydrogen, alkyl, halogen, hydroxyl, nitro, alkoxy, amino, haloalkyl, aryl, heteroaryl, alkoxyalkyl, aminoalkyl, hydroxyalkyl, thioalkyl, alkylamino, arylamino, alkylsulfonylamino, acyl, acylamino, sulfonyl, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, alkynylalkyl, carboxy, alkoxycarbonyl, carboxamido, cyano and $-(CH_2)_n-COR$ wherein n is $[[0-2]]$ an integer selected from the group consisting of zero, 1 and 2, and R is selected from the group consisting of hydroxyl, alkoxy, alkyl and amino;

















X is selected from the group consisting of $-O-$, CO , SO_2 , NR^m and $(CHR^p)_n$; wherein R^p and R^m are H or alkyl, n is $[[0-2]]$ an integer selected from the group consisting of zero, 1 and 2;

R^b is X_3-R^h wherein X_3 is selected from the group consisting of O , S and NR^j wherein R^h and R^j are independently selected from the group consisting of H , alkyl, acyl, aryl, aralkyl and alkoxyalkyl; and




$A1$ is selected from the group consisting of:

Amendment B
U.S. Appl. 09/942,174
May 11, 2004



Amendment B
U.S. Appl. 09/942,174
May 11, 2004



and pharmaceutically acceptable salts, isomers, enantiomers, tautomers, racemates or polymorphs thereof,

wherein

m is an integer selected from the group consisting of 1 and 2;

B^1 is selected from the group consisting of CH_2 , O , CO , S , CF_2 , SO_2 and NR^a ;

B^2 is selected from the group consisting of N and CH ;

B^3 is selected from the group consisting of N and CH ;

B^4 is selected from the group consisting of NH , O and S ;

B^5 is selected from the group consisting of NH , O and S ;

B^6 is selected from the group consisting of N and CH ;

Amendment B
U.S. Appl. 09/942,174
May 11, 2004

B⁷ is selected from the group consisting of CH₂, O, CO, S, CF₂, SO₂ and NR^a;

R⁷⁹ is selected from the group consisting of OR^a, OH, H and Me;

R⁸⁰ is selected from the group consisting of H and Me;

R⁸¹ is selected from the group consisting of OR^a, OH and Me;

X⁷ is selected from the group consisting of O, S, NR^a, SO₂ and CF₂;

X⁸ is selected from the group consisting of CH₂, O, S, NR^a, SO₂ and CONR^a; and

R^a is selected from the group consisting of H, alkyl and amino.

9. (currently amended) A compound according to claim 8 wherein said compound is 1,2,3,4-tetrahydro-1-oxo-6-[3-(2-tetrahydropyrimidinyl)amino]-propoxy]-2-isoquinolineacetic acid 1,2,3,4-tetrahydro-1-oxo-[6-[3-(2-tetrahydropyrimidinyl)amino]-propoxy]-2- isoquinolineacetic acid, and pharmaceutically acceptable salts, isomers, enantiomers, tautomers, racemates or polymorphs thereof.

10. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 8 and a pharmaceutically acceptable carrier.

11. (currently amended) A method for treating ~~conditions~~ a condition mediated by the $\alpha_v\beta_3$ integrin selected from the group consisting of tumor metastasis, tumor growth, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy and arthritis in a mammal in need of such treatment comprising administering an effective $\alpha_v\beta_3$ inhibiting amount of a compound of claim 8.

12. (canceled).

13. (currently amended) A method for treating ~~conditions~~ a condition mediated by the $\alpha_v\beta_5$ integrin selected from the group consisting of tumor metastasis, tumor growth, solid tumor

Amendment B
U.S. Appl. 09/942,174
May 11, 2004

growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy and arthritis in a mammal in need of such treatment comprising administering an effective $\alpha_v\beta_3$ inhibiting amount of a compound of claim 8.

14. (canceled).

15. (previously presented) A method of treating neoplasia in a patient in need thereof comprising administering a compound of claim 8 in combination with a chemotherapeutic agent.

16. (canceled).